

Global Peptide Cancer Vaccine Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/G861D26DCEABEN.html>

Date: April 2024

Pages: 192

Price: US\$ 4,950.00 (Single User License)

ID: G861D26DCEABEN

Abstracts

Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and GenereX Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.

Peptide Cancer Vaccine segment by Company

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

Peptide Cancer Vaccine segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Peptide Cancer Vaccine segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide Cancer Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Cancer Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each

segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

1.1 Product Definition

1.2 Peptide Cancer Vaccine Market by Pipeline

1.2.1 Global Peptide Cancer Vaccine Market Size by Pipeline, 2019 VS 2023 VS 2030

1.2.2 ITK-1

1.2.3 GRN-1201

1.2.4 TPIV200

1.2.5 TPIV110

1.2.6 UV1

1.2.7 Galinpepimut-S

1.2.8 TARP 27-35

1.2.9 HER-Vaxx

1.2.10 Vx-001

1.2.11 Others

1.3 Peptide Cancer Vaccine Market by Application

1.3.1 Global Peptide Cancer Vaccine Market Size by Application, 2019 VS 2023 VS 2030

1.3.2 Breast Cancer

1.3.3 Lung Cancer

1.3.4 Melanoma

1.3.5 Prostate Cancer

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Goals and Objectives

2 PEPTIDE CANCER VACCINE MARKET DYNAMICS

2.1 Peptide Cancer Vaccine Industry Trends

2.2 Peptide Cancer Vaccine Industry Drivers

2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges

2.4 Peptide Cancer Vaccine Industry Restraints

3 GLOBAL MARKET GROWTH PROSPECTS

3.1 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts (2019-2030)

3.2 Global Peptide Cancer Vaccine Revenue by Region

- 3.2.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
- 3.2.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
- 3.2.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
- 3.2.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
- 3.3 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2019-2030
- 3.4 Global Peptide Cancer Vaccine Sales by Region
 - 3.4.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
 - 3.4.2 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
 - 3.4.3 Global Peptide Cancer Vaccine Sales by Region (2025-2030)
 - 3.4.4 Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2030)
- 3.5 US & Canada
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 Middle East, Africa and Latin America

4 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 4.1 Global Peptide Cancer Vaccine Revenue by Manufacturers
 - 4.1.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
 - 4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
 - 4.1.3 Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2023
- 4.2 Global Peptide Cancer Vaccine Sales by Manufacturers
 - 4.2.1 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
 - 4.2.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
 - 4.2.3 Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2023
- 4.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2019-2024)
- 4.4 Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
- 4.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
- 4.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
- 4.8 Market Competitive Analysis
 - 4.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI

4.8.2 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier

5 PEPTIDE CANCER VACCINE MARKET BY TYPE

5.1 Global Peptide Cancer Vaccine Revenue by Type

5.1.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)

5.1.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030) & (US\$ Million)

5.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)

5.2 Global Peptide Cancer Vaccine Sales by Type

5.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)

5.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030) & (K Doses)

5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)

5.3 Global Peptide Cancer Vaccine Price by Type

6 PEPTIDE CANCER VACCINE MARKET BY APPLICATION

6.1 Global Peptide Cancer Vaccine Revenue by Application

6.1.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)

6.1.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030) & (US\$ Million)

6.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)

6.2 Global Peptide Cancer Vaccine Sales by Application

6.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)

6.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (K Doses)

6.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)

6.3 Global Peptide Cancer Vaccine Price by Application

7 COMPANY PROFILES

7.1 Boston Biomedical

7.1.1 Boston Biomedical Company Information

7.1.2 Boston Biomedical Business Overview

7.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

7.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio

7.1.5 Boston Biomedical Recent Developments

7.2 Ultimovacs

- 7.2.1 Ultimovacs Company Information
- 7.2.2 Ultimovacs Business Overview
- 7.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
- 7.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
- 7.2.5 Ultimovacs Recent Developments
- 7.3 BrightPath Biotherapeutics
 - 7.3.1 BrightPath Biotherapeutics Company Information
 - 7.3.2 BrightPath Biotherapeutics Business Overview
 - 7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
 - 7.3.5 BrightPath Biotherapeutics Recent Developments
- 7.4 TapImmune
 - 7.4.1 TapImmune Company Information
 - 7.4.2 TapImmune Business Overview
 - 7.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
 - 7.4.5 TapImmune Recent Developments
- 7.5 Immatix
 - 7.5.1 Immatix Company Information
 - 7.5.2 Immatix Business Overview
 - 7.5.3 Immatix Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.5.4 Immatix Peptide Cancer Vaccine Product Portfolio
 - 7.5.5 Immatix Recent Developments
- 7.6 Sellas
 - 7.6.1 Sellas Company Information
 - 7.6.2 Sellas Business Overview
 - 7.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
 - 7.6.5 Sellas Recent Developments
- 7.7 Imugene
 - 7.7.1 Imugene Company Information
 - 7.7.2 Imugene Business Overview
 - 7.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

- 7.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
- 7.7.5 Imugene Recent Developments
- 7.8 VAXON Biotech
 - 7.8.1 VAXON Biotech Company Information
 - 7.8.2 VAXON Biotech Business Overview
 - 7.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
 - 7.8.5 VAXON Biotech Recent Developments
- 7.9 Generex Biotechnology
 - 7.9.1 Generex Biotechnology Company Information
 - 7.9.2 Generex Biotechnology Business Overview
 - 7.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
 - 7.9.5 Generex Biotechnology Recent Developments
- 7.10 ISA Pharmaceuticals
 - 7.10.1 ISA Pharmaceuticals Company Information
 - 7.10.2 ISA Pharmaceuticals Business Overview
 - 7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
 - 7.10.5 ISA Pharmaceuticals Recent Developments
- 7.11 OncoTherapy Science
 - 7.11.1 OncoTherapy Science Company Information
 - 7.11.2 OncoTherapy Science Business Overview
 - 7.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 7.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
 - 7.11.5 OncoTherapy Science Recent Developments

8 NORTH AMERICA

- 8.1 North America Peptide Cancer Vaccine Market Size by Pipeline
 - 8.1.1 North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 8.1.2 North America Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
 - 8.1.3 North America Peptide Cancer Vaccine Price by Pipeline (2019-2030)
- 8.2 North America Peptide Cancer Vaccine Market Size by Application
 - 8.2.1 North America Peptide Cancer Vaccine Revenue by Application (2019-2030)

- 8.2.2 North America Peptide Cancer Vaccine Sales by Application (2019-2030)
- 8.2.3 North America Peptide Cancer Vaccine Price by Application (2019-2030)
- 8.3 North America Peptide Cancer Vaccine Market Size by Country
 - 8.3.1 North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
 - 8.3.2 North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
 - 8.3.3 North America Peptide Cancer Vaccine Price by Country (2019-2030)
 - 8.3.4 U.S.
 - 8.3.5 Canada

9 EUROPE

- 9.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
 - 9.1.1 Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 9.1.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
 - 9.1.3 Europe Peptide Cancer Vaccine Price by Pipeline (2019-2030)
- 9.2 Europe Peptide Cancer Vaccine Market Size by Application
 - 9.2.1 Europe Peptide Cancer Vaccine Revenue by Application (2019-2030)
 - 9.2.2 Europe Peptide Cancer Vaccine Sales by Application (2019-2030)
 - 9.2.3 Europe Peptide Cancer Vaccine Price by Application (2019-2030)
- 9.3 Europe Peptide Cancer Vaccine Market Size by Country
 - 9.3.1 Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
 - 9.3.2 Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
 - 9.3.3 Europe Peptide Cancer Vaccine Price by Country (2019-2030)
 - 9.3.4 Germany
 - 9.3.5 France
 - 9.3.6 U.K.
 - 9.3.7 Italy
 - 9.3.8 Russia

10 CHINA

- 10.1 China Peptide Cancer Vaccine Market Size by Pipeline
 - 10.1.1 China Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 10.1.2 China Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
 - 10.1.3 China Peptide Cancer Vaccine Price by Pipeline (2019-2030)
- 10.2 China Peptide Cancer Vaccine Market Size by Application

- 10.2.1 China Peptide Cancer Vaccine Revenue by Application (2019-2030)
- 10.2.2 China Peptide Cancer Vaccine Sales by Application (2019-2030)
- 10.2.3 China Peptide Cancer Vaccine Price by Application (2019-2030)

11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Peptide Cancer Vaccine Market Size by Pipeline
 - 11.1.1 Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 11.1.2 Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
 - 11.1.3 Asia Peptide Cancer Vaccine Price by Pipeline (2019-2030)
- 11.2 Asia Peptide Cancer Vaccine Market Size by Application
 - 11.2.1 Asia Peptide Cancer Vaccine Revenue by Application (2019-2030)
 - 11.2.2 Asia Peptide Cancer Vaccine Sales by Application (2019-2030)
 - 11.2.3 Asia Peptide Cancer Vaccine Price by Application (2019-2030)
- 11.3 Asia Peptide Cancer Vaccine Market Size by Country
 - 11.3.1 Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
 - 11.3.2 Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
 - 11.3.3 Asia Peptide Cancer Vaccine Price by Country (2019-2030)
 - 11.3.4 Japan
 - 11.3.5 South Korea
 - 11.3.6 India
 - 11.3.7 Australia
 - 11.3.8 China Taiwan
 - 11.3.9 Southeast Asia

12 MIDDLE EAST, AFRICA AND LATIN AMERICA

- 12.1 MEALA Peptide Cancer Vaccine Market Size by Pipeline
 - 12.1.1 MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 12.1.2 MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
 - 12.1.3 MEALA Peptide Cancer Vaccine Price by Pipeline (2019-2030)
- 12.2 MEALA Peptide Cancer Vaccine Market Size by Application
 - 12.2.1 MEALA Peptide Cancer Vaccine Revenue by Application (2019-2030)
 - 12.2.2 MEALA Peptide Cancer Vaccine Sales by Application (2019-2030)
 - 12.2.3 MEALA Peptide Cancer Vaccine Price by Application (2019-2030)
- 12.3 MEALA Peptide Cancer Vaccine Market Size by Country
 - 12.3.1 MEALA Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)

12.3.2 MEALA Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)

12.3.3 MEALA Peptide Cancer Vaccine Price by Country (2019-2030)

12.3.4 Mexico

12.3.5 Brazil

12.3.6 Israel

12.3.7 Argentina

12.3.8 Colombia

12.3.9 Turkey

12.3.10 Saudi Arabia

12.3.11 UAE

13 VALUE CHAIN AND SALES CHANNELS ANALYSIS

13.1 Peptide Cancer Vaccine Value Chain Analysis

13.1.1 Peptide Cancer Vaccine Key Raw Materials

13.1.2 Raw Materials Key Suppliers

13.1.3 Manufacturing Cost Structure

13.1.4 Peptide Cancer Vaccine Production Mode & Process

13.2 Peptide Cancer Vaccine Sales Channels Analysis

13.2.1 Direct Comparison with Distribution Share

13.2.2 Peptide Cancer Vaccine Distributors

13.2.3 Peptide Cancer Vaccine Customers

14 CONCLUDING INSIGHTS

15 APPENDIX

15.1 Reasons for Doing This Study

15.2 Research Methodology

15.3 Research Process

15.4 Authors List of This Report

15.5 Data Source

15.5.1 Secondary Sources

15.5.2 Primary Sources

15.6 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US\$ Million), 2019 VS 2023 VS 2030

Table 2. ITK-1 Major Manufacturers

Table 3. GRN-1201 Major Manufacturers

Table 4. TPIV200 Major Manufacturers

Table 5. TPIV110 Major Manufacturers

Table 6. UV1 Major Manufacturers

Table 7. Galinpepimut-S Major Manufacturers

Table 8. TARP 27-35 Major Manufacturers

Table 9. HER-Vaxx Major Manufacturers

Table 10. Vx-001 Major Manufacturers

Table 11. Others Major Manufacturers

Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030

Table 13. Breast Cancer Major Manufacturers

Table 14. Lung Cancer Major Manufacturers

Table 15. Melanoma Major Manufacturers

Table 16. Prostate Cancer Major Manufacturers

Table 17. Others Major Manufacturers

Table 18. Peptide Cancer Vaccine Industry Trends

Table 19. Peptide Cancer Vaccine Industry Drivers

Table 20. Peptide Cancer Vaccine Industry Opportunities and Challenges

Table 21. Peptide Cancer Vaccine Industry Restraints

Table 22. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Table 23. Global Peptide Cancer Vaccine Revenue by Region (2019-2024) & (US\$ Million)

Table 24. Global Peptide Cancer Vaccine Revenue by Region (2025-2030) & (US\$ Million)

Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)

Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Region (2025-2030)

Table 27. Global Peptide Cancer Vaccine Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Doses)

- Table 28. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
- Table 29. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)
- Table 30. Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
- Table 31. Global Peptide Cancer Vaccine Sales Market Share by Region (2025-2030)
- Table 32. Global Peptide Cancer Vaccine Revenue by Manufacturers (US\$ Million) & (2019-2024)
- Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
- Table 34. Global Peptide Cancer Vaccine Sales by Manufacturers (US\$ Million) & (2019-2024)
- Table 35. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
- Table 36. Global Peptide Cancer Vaccine Sales Price (USD/Dose) of Manufacturers (2019-2024)
- Table 37. Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
- Table 38. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- Table 39. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
- Table 40. Global Peptide Cancer Vaccine Manufacturers Commercialization Time
- Table 41. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 42. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
- Table 43. Global Peptide Cancer Vaccine Revenue by Pipeline 2019 VS 2023 VS 2030 (US\$ Million)
- Table 44. Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)
- Table 45. Global Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)
- Table 46. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2024)
- Table 47. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2025-2030)
- Table 48. Global Peptide Cancer Vaccine Sales by Pipeline 2019 VS 2023 VS 2030 (K Doses)
- Table 49. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
- Table 50. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
- Table 51. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
- Table 52. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2025-2030)

Table 53. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)

Table 54. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)

Table 55. Global Peptide Cancer Vaccine Revenue by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 56. Global Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)

Table 57. Global Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)

Table 58. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)

Table 59. Global Peptide Cancer Vaccine Revenue Market Share by Application (2025-2030)

Table 60. Global Peptide Cancer Vaccine Sales by Application 2019 VS 2023 VS 2030 (K Doses)

Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 62. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 63. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)

Table 64. Global Peptide Cancer Vaccine Sales Market Share by Application (2025-2030)

Table 65. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)

Table 66. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)

Table 67. Boston Biomedical Company Information

Table 68. Boston Biomedical Business Overview

Table 69. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 70. Boston Biomedical Peptide Cancer Vaccine Product Portfolio

Table 71. Boston Biomedical Recent Development

Table 72. Ultimovacs Company Information

Table 73. Ultimovacs Business Overview

Table 74. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 75. Ultimovacs Peptide Cancer Vaccine Product Portfolio

Table 76. Ultimovacs Recent Development

Table 77. BrightPath Biotherapeutics Company Information

- Table 78. BrightPath Biotherapeutics Business Overview
- Table 79. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 80. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
- Table 81. BrightPath Biotherapeutics Recent Development
- Table 82. TapImmune Company Information
- Table 83. TapImmune Business Overview
- Table 84. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 85. TapImmune Peptide Cancer Vaccine Product Portfolio
- Table 86. TapImmune Recent Development
- Table 87. Immatix Company Information
- Table 88. Immatix Business Overview
- Table 89. Immatix Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 90. Immatix Peptide Cancer Vaccine Product Portfolio
- Table 91. Immatix Recent Development
- Table 92. Sellas Company Information
- Table 93. Sellas Business Overview
- Table 94. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 95. Sellas Peptide Cancer Vaccine Product Portfolio
- Table 96. Sellas Recent Development
- Table 97. Imugene Company Information
- Table 98. Imugene Business Overview
- Table 99. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 100. Imugene Peptide Cancer Vaccine Product Portfolio
- Table 101. Imugene Recent Development
- Table 102. VAXON Biotech Company Information
- Table 103. VAXON Biotech Business Overview
- Table 104. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 105. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
- Table 106. VAXON Biotech Recent Development
- Table 107. Generex Biotechnology Company Information
- Table 108. Generex Biotechnology Business Overview
- Table 109. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

- Table 110. GenereX Biotechnology Peptide Cancer Vaccine Product Portfolio
- Table 111. GenereX Biotechnology Recent Development
- Table 112. ISA Pharmaceuticals Company Information
- Table 113. ISA Pharmaceuticals Business Overview
- Table 114. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 115. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- Table 116. ISA Pharmaceuticals Recent Development
- Table 117. OncoTherapy Science Company Information
- Table 118. OncoTherapy Science Business Overview
- Table 119. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
- Table 120. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- Table 121. OncoTherapy Science Recent Development
- Table 122. North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)
- Table 123. North America Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)
- Table 124. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
- Table 125. North America Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
- Table 126. North America Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
- Table 127. North America Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
- Table 128. North America Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)
- Table 129. North America Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)
- Table 130. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
- Table 131. North America Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
- Table 132. North America Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
- Table 133. North America Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
- Table 134. North America Peptide Cancer Vaccine Revenue Grow Rate by Country

(2019 VS 2023 VS 2030) & (US\$ Million)

Table 135. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US\$ Million)

Table 136. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US\$ Million)

Table 137. North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)

Table 138. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 139. North America Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)

Table 140. North America Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)

Table 141. North America Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)

Table 142. US Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 143. Canada Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 144. Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 145. Europe Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)

Table 146. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 147. Europe Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)

Table 148. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)

Table 149. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)

Table 150. Europe Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)

Table 151. Europe Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)

Table 152. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 153. Europe Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 154. Europe Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)

Table 155. Europe Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)

Table 156. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 157. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US\$ Million)

Table 158. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US\$ Million)

Table 159. Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)

Table 160. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 161. Europe Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)

Table 162. Europe Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)

Table 163. Europe Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)

Table 164. Germany Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 165. France Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 166. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 167. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 168. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 169. China Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 170. China Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)

Table 171. China Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 172. China Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)

Table 173. China Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)

Table 174. China Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)

Table 175. China Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)

Table 176. China Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)

Table 177. China Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 178. China Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 179. China Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)

Table 180. China Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)

Table 181. Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 182. Asia Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)

Table 183. Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 184. Asia Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)

Table 185. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)

Table 186. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)

Table 187. Asia Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)

Table 188. Asia Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)

Table 189. Asia Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 190. Asia Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 191. Asia Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)

Table 192. Asia Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)

Table 193. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 194. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US\$ Million)

Table 195. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US\$ Million)

Table 196. Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)

Table 197. Asia Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 198. Asia Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)

Table 199. Asia Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)

Table 200. Asia Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)

Table 201. Japan Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 202. South Korea Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 203. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 204. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 205. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 206. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 207. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 208. Peptide Cancer Vaccine Revenue (2019-2030) & (US\$ Million)

Table 209. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 210. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US\$ Million)

Table 211. MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 212. MEALA Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)

Table 213. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)

Table 214. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)

Table 215. MEALA Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US\$ Million)

Table 216. MEALA Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US\$ Million)

Table 217. MEALA Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 218. MEALA Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 219. ME

I would like to order

Product name: Global Peptide Cancer Vaccine Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/G861D26DCEABEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G861D26DCEABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970